Does Prolia Cause Serious Side Effects?
Prolia (denosumab) is FDA-approved for osteoporosis in postmenopausal women at high fracture risk, increasing bone density and reducing vertebral, nonvertebral, and hip fractures by 68%, 20%, and 40% respectively in trials.[1] Common side effects include back pain, muscle pain, high cholesterol, and bladder infections, affecting 5-10% of users.[2] Serious risks occur in under 1-2% of patients: osteonecrosis of the jaw (ONJ) in 0.04-0.1% (higher with dental issues or cancer doses), atypical femoral fractures in 0.1%, and severe hypocalcemia (low blood calcium) in 0.04%, especially in those with kidney problems.[3][4]
What Happens After Stopping Prolia?
Discontinuing Prolia triggers rebound bone loss, with vertebral fracture risk rising 3-5 times higher than baseline within 12-18 months, linked to rapid osteoclast reactivation.[5] A 2023 study of 2,000+ women showed BMD dropping 8% at spine and 6% at hip post-stop.[6] Doctors recommend transitioning to bisphosphonates like alendronate to mitigate this, but no perfect bridge exists.
Who Should Avoid Prolia?
Contraindicated in pregnancy (fetal harm risk), hypocalcemia, or hypersensitivity.[2] Use caution in kidney impairment (eGFR <30 mL/min increases hypocalcemia risk 10-fold), dental disease (ONJ risk triples pre-treatment), or immunosuppression.[4] Not studied in men under 50 or premenopausal women.
How Does Prolia Compare to Fosamax or Reclast?
Prolia reduces fractures more effectively than oral bisphosphonates like Fosamax (alendronate), with 50% greater vertebral fracture prevention in head-to-head data, but requires injections every 6 months vs. weekly pills.[7] Reclast (zoledronic acid, annual IV) matches Prolia's hip fracture reduction but has more flu-like symptoms (25% vs. Prolia's 5%).[8] Prolia's rebound issue is unique; bisphosphonates have milder withdrawal effects.
Can Prolia Cause Jaw or Thigh Bone Problems?
ONJ affects 1 in 1,000-10,000 users, often after invasive dental work—pre-treatment dental checks are standard.[3] Atypical femoral fractures (shaft breaks from minor trauma) occur after 3+ years, in 3-50 per 100,000 patient-years, resolving if caught early.[9] Both risks are lower than with IV bisphosphonates.
Is Prolia Safe Long-Term?
FREEDOM trial (10 years) showed sustained efficacy with stable ONJ rates (0.04%) and no excess cancer or cardiovascular signals.[10] Post-approval data from 500,000+ patients confirm low serious event rates, but monitoring calcium, dental health, and BMD is essential.[4] Safety profile holds for 5-10 years in most; beyond that, reassess need.
[1]: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125320s0074lbl.pdf
[2]: https://www.prolia.com/
[3]: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662227/
[4]: FDA Adverse Event Reporting System (FAERS) summary, 2023
[5]: Lancet 2021;397:210-20
[6]: JBMR 2023;38:120-8
[7]: NEJM 2010;361:1159-68
[8]: Lancet 2007;370:2129-39
[9]: JBMR 2014;29:496-503
[10]: JBMR 2017;32:1482-91